

# Barbara Schmalfeldt

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1334120/publications.pdf>

Version: 2024-02-01

85  
papers

1,409  
citations

361413

20  
h-index

395702

33  
g-index

89  
all docs

89  
docs citations

89  
times ranked

2432  
citing authors

#	ARTICLE	IF	CITATIONS
1	Insights into the Steps of Breast Cancerâ€“Brain Metastases Development: Tumor Cell Interactions with the Bloodâ€“Brain Barrier. <i>International Journal of Molecular Sciences</i> , 2022, 23, 1900.	4.1	8
2	Navigating through the Lipid Metabolism Maze: Diagnosis and Prognosis Metabolites of Hepatocellular Carcinoma versus Compensated Cirrhosis. <i>Journal of Clinical Medicine</i> , 2022, 11, 1292.	2.4	0
3	Randomised controlled trial testing the feasibility of an exercise and nutrition intervention for patients with ovarian cancer during and after first-line chemotherapy (BENITA-study). <i>BMJ Open</i> , 2022, 12, e054091.	1.9	7
4	Tissue-Specific Expression of TIGIT, PD-1, TIM-3, and CD39 by $\gamma\delta$ T Cells in Ovarian Cancer. <i>Cells</i> , 2022, 11, 964.	4.1	19
5	The added value of CEUS and ultrasound-guided biopsy in diagnosing an aggressive desmoplastic small round cell tumour of peritoneum in a young male. A case report. <i>Medical Ultrasonography</i> , 2022, 24, 499.	0.8	1
6	Contrast enhancement for ultrasound-guided interventions: when to use it and what to expect?. <i>Ultrasonography</i> , 2022, 41, 263-278.	2.3	6
7	Novel approaches in search for biomarkers of cholangiocarcinoma. <i>World Journal of Gastroenterology</i> , 2022, 28, 1508-1525.	3.3	3
8	Outcome of liver cancer patients with SARSâ€“CoVâ€“2 infection: An International, Multicentre, Cohort Study. <i>Liver International</i> , 2022, 42, 1891-1901.	3.9	11
9	Pulmonary complications of portal hypertension: The overlooked decompensation. <i>World Journal of Clinical Cases</i> , 2022, 10, 5531-5540.	0.8	2
10	Bleeding after Microwave Ablation in Hepatocellular Carcinoma: Successful Treatment with Percutaneous Ultrasound-Guided Cyanoacrylate Glue Embolization. <i>Ultraschall in Der Medizin</i> , 2021, 42, 202-203.	1.5	2
11	Demand for integrative medicine among women with breast and gynecological cancer: a multicenter cross-sectional study in Southern and Northern Germany. <i>Archives of Gynecology and Obstetrics</i> , 2021, 303, 1315-1330.	1.7	11
12	Gynecologistsâ€™ attitudes toward and use of complementary and integrative medicine approaches: results of a national survey in Germany. <i>Archives of Gynecology and Obstetrics</i> , 2021, 303, 967-980.	1.7	11
13	Treatment of hepatitis C virus infection in patients with hepatocellular carcinoma: Truth or dare?. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2021, 36, 1518-1528.	2.8	2
14	Aging influences pulmonary artery flow and stiffness in healthy individuals: non-invasive assessment using cardiac MRI. <i>Clinical Radiology</i> , 2021, 76, 161.e19-161.e28.	1.1	10
15	CAMK2N1/RUNX3 methylation is an independent prognostic biomarker for progression-free and overall survival of platinum-sensitive epithelial ovarian cancer patients. <i>Clinical Epigenetics</i> , 2021, 13, 15.	4.1	10
16	The effect of family history on screening procedures and prognosis in breast cancer patients - Results of a large population-based case-control study. <i>Breast</i> , 2021, 55, 98-104.	2.2	10
17	Ultrasound or Sectional Imaging Techniques as Screening Tools for Hepatocellular Carcinoma: Fall Forward or Move Forward?. <i>Journal of Clinical Medicine</i> , 2021, 10, 903.	2.4	9
18	Plasma fetal bile acids 7 $\alpha$ -hydroxy-3-oxochol-4-en-24-oic acid and 3-oxachola-4,6-dien-24-oic acid indicate severity of liver cirrhosis. <i>Scientific Reports</i> , 2021, 11, 8298.	3.3	5

#	ARTICLE	IF	CITATIONS
19	Serum levels of soluble programmed death-ligand 1 (sPD-L1): A possible biomarker in predicting post-treatment outcomes in patients with early hepatocellular carcinoma. <i>International Immunopharmacology</i> , 2021, 94, 107467.	3.8	18
20	Assessing the impact of COVID-19 on liver cancer management (CERO-19). <i>JHEP Reports</i> , 2021, 3, 100260.	4.9	36
21	Viscoelastic tests in liver disease: where do we stand now?. <i>World Journal of Gastroenterology</i> , 2021, 27, 3290-3302.	3.3	16
22	Molecular characteristics and tumorigenicity of ascites-derived tumor cells: mitochondrial oxidative phosphorylation as a novel therapy target in ovarian cancer. <i>Molecular Oncology</i> , 2021, 15, 3578-3595.	4.6	14
23	MUC5AC expression is linked to mucinous/endometrioid subtype, absence of nodal metastasis and mismatch repair deficiency in ovarian cancer. <i>Pathology Research and Practice</i> , 2021, 224, 153533.	2.3	3
24	High mitochondrial content is associated with breast cancer aggressiveness. <i>Molecular and Clinical Oncology</i> , 2021, 15, 203.	1.0	3
25	Hepatic Hydrothorax – An Independent Decompensating Event Associated with Long-Term Mortality in Patients with Cirrhosis. <i>Journal of Clinical Medicine</i> , 2021, 10, 3688.	2.4	11
26	Percutaneous ultrasound guided PEG-coated gold nanoparticles enhanced radiofrequency ablation in liver. <i>Scientific Reports</i> , 2021, 11, 1316.	3.3	4
27	<i>BRCA1</i> promoter hypermethylation on circulating tumor DNA correlates with improved survival of patients with ovarian cancer. <i>Molecular Oncology</i> , 2021, 15, 3615-3625.	4.6	8
28	6q deletion is frequent but unrelated to patient prognosis in breast cancer. <i>Breast Cancer</i> , 2021, , 1.	2.9	1
29	Extracellular vesicles small RNA clusters: hit the nail on the head of liver cancer detection. <i>Hepatobiliary Surgery and Nutrition</i> , 2021, 11, 0-0.	1.5	4
30	Endoscopic or percutaneous biliary drainage in hilar cholangiocarcinoma: When and how?. <i>World Journal of Gastrointestinal Oncology</i> , 2021, 13, 2050-2063.	2.0	14
31	Evaluation of a program for routine implementation of shared decision-making in cancer care: results of a stepped wedge cluster randomized trial. <i>Implementation Science</i> , 2021, 16, 106.	6.9	13
32	Combined treatments in hepatocellular carcinoma: Time to put them in the guidelines?. <i>World Journal of Gastrointestinal Oncology</i> , 2021, 13, 1896-1918.	2.0	5
33	Transcriptome Analysis in Vulvar Squamous Cell Cancer. <i>Cancers</i> , 2021, 13, 6372.	3.7	3
34	Clinical relevance of H-RAS, K-RAS, and N-RAS mRNA expression in primary breast cancer patients. <i>Breast Cancer Research and Treatment</i> , 2020, 179, 403-414.	2.5	16
35	An exercise and nutrition intervention for ovarian cancer patients during and after first-line chemotherapy (BENITA study): a randomized controlled pilot trial. <i>International Journal of Gynecological Cancer</i> , 2020, 30, 541-545.	2.5	5
36	Cerebral metastasis in recurrent squamous cell carcinoma of the vulva: case report and review of the literature. <i>Archives of Gynecology and Obstetrics</i> , 2020, 301, 327-332.	1.7	2

#	ARTICLE	IF	CITATIONS
37	EVs as Potential New Therapeutic Tool/Target in Gastrointestinal Cancer and HCC. <i>Cancers</i> , 2020, 12, 3019.	3.7	18
38	P1341 An old patient with two tales: left cor triatriatum and atrial septal defect. <i>European Heart Journal Cardiovascular Imaging</i> , 2020, 21, .	1.2	0
39	Performance of coronary calcium score and epicardial fat volume in early diagnostic of coronary artery disease. <i>European Heart Journal</i> , 2020, 41, .	2.2	0
40	Liquid Biopsies in Hepatocellular Carcinoma: Are We Winning?. <i>Journal of Clinical Medicine</i> , 2020, 9, 1541.	2.4	38
41	Genomic characterization of vulvar squamous cell carcinoma. <i>Gynecologic Oncology</i> , 2020, 158, 547-554.	1.4	21
42	Synergistic effects of extracellular vesicle phenotyping and AFP in hepatobiliary cancer differentiation. <i>Liver International</i> , 2020, 40, 3103-3116.	3.9	20
43	Mechanisms of Tumor-Lymphatic Interactions in Invasive Breast and Prostate Carcinoma. <i>International Journal of Molecular Sciences</i> , 2020, 21, 602.	4.1	15
44	High homogeneity of MMR deficiency in ovarian cancer. <i>Gynecologic Oncology</i> , 2020, 156, 669-675.	1.4	24
45	Course of cervical intraepithelial neoplasia diagnosed during pregnancy. <i>Archives of Gynecology and Obstetrics</i> , 2020, 301, 1503-1512.	1.7	11
46	Bevacizumab and platinum-based combinations for recurrent ovarian cancer: a randomised, open-label, phase 3 trial. <i>Lancet Oncology</i> , The, 2020, 21, 699-709.	10.7	104
47	Microwave ablation in the treatment of liver tumors. A better tool or simply more power?. <i>Medical Ultrasonography</i> , 2020, 22, 451.	0.8	7
48	Hepatocellular Carcinoma Occurrence and Recurrence after Antiviral Treatment in HCV-Related Cirrhosis. Are Outcomes Different after Direct Antiviral Agents? A Review. <i>Journal of Gastrointestinal and Liver Diseases</i> , 2020, 26, 403-410.	0.9	8
49	NOGGO Ov-42/MAMOC: Rucaparib maintenance after bevacizumab maintenance following carboplatin-based first line-chemotherapy in ovarian cancer patients.. <i>Journal of Clinical Oncology</i> , 2020, 38, TPS6102-TPS6102.	1.6	3
50	Pelvic Lymphadenectomy in Vulvar Cancer – Does it make sense?. <i>Geburtshilfe Und Frauenheilkunde</i> , 2020, 80, 1221-1228.	1.8	2
51	Real-Time Contrast-Enhanced – Guided Biopsy Compared with Conventional Ultrasound – Guided Biopsy in the Diagnosis of Hepatic Tumors on a Background of Advanced Chronic Liver Disease: A Prospective, Randomized, Clinical Trial. <i>Ultrasound in Medicine and Biology</i> , 2019, 45, 2915-2924.	1.5	12
52	A shift from membranous and stromal syndecan – 1 (CD138) expression to cytoplasmic CD138 expression is associated with poor prognosis in breast cancer. <i>Molecular Carcinogenesis</i> , 2019, 58, 2306-2315.	2.7	14
53	Predictive factors for lymph node metastases in vulvar cancer. An analysis of the AGO-CaRE-1 multicenter study. <i>Gynecologic Oncology</i> , 2019, 154, 565-570.	1.4	16
54	Superficially invasive stage IA vulvar squamous cell carcinoma – therapy and prognosis. <i>International Journal of Gynecological Cancer</i> , 2019, 29, 466-473.	2.5	8

#	ARTICLE	IF	CITATIONS
55	Extracellular Vesicles in Liver Diseases: Diagnostic, Prognostic, and Therapeutic Application. <i>Seminars in Liver Disease</i> , 2019, 39, 070-077.	3.6	35
56	What is the evidence for lymphadenectomy in presumed early ovarian cancer?. <i>Archives of Gynecology and Obstetrics</i> , 2019, 299, 1-5.	1.7	1
57	Programmed cell death protein-1 (PD-1)/programmed death-ligand-1 (PD-L1) axis in hepatocellular carcinoma: prognostic and therapeutic perspectives. <i>Clinical and Translational Oncology</i> , 2019, 21, 702-712.	2.4	38
58	Percutaneous ultrasound guided radiofrequency and microwave ablation in the treatment of hepatic metastases. A monocentric initial experience.. <i>Medical Ultrasonography</i> , 2019, 21, 217.	0.8	13
59	Up-regulation of lysophosphatidylcholine acyltransferase 1 (LPCAT1) is linked to poor prognosis in breast cancer. <i>Aging</i> , 2019, 11, 7796-7804.	3.1	33
60	EUDARIO/ENGOTov-48: A European multicenter randomised phase II trial on the combination of the HSP90 inhibitor ganetespib with carboplatin followed by maintenance treatment with niraparib (+/-) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 5 platinum-sensitive ovarian cancer patients.. <i>Journal of Clinical Oncology</i> , 2019, 37, TPS5605-TPS5605.	1.6	0
61	Reduced mannosidase MAN1A1 expression leads to aberrant N-glycosylation and impaired survival in breast cancer. <i>British Journal of Cancer</i> , 2018, 118, 847-856.	6.4	49
62	Comparison of PapilloCheck and linear array to detect and differentiate human papillomaviruses in cervical and tonsillar smears from females with cervical intraepithelial lesions. <i>European Journal of Microbiology and Immunology</i> , 2018, 8, 107-111.	2.8	1
63	Contemporary role of liver biopsy in hepatocellular carcinoma. <i>World Journal of Hepatology</i> , 2018, 10, 452-461.	2.0	31
64	Prognostic Impact of CEACAM1 in Node-Negative Ovarian Cancer Patients. <i>Disease Markers</i> , 2018, 2018, 1-10.	1.3	8
65	Prognostic role of the sialyltransferase ST6GAL1 in ovarian cancer. <i>Glycobiology</i> , 2018, 28, 898-903.	2.5	37
66	Clinical relevance of cytoskeleton associated proteins for ovarian cancer. <i>Journal of Cancer Research and Clinical Oncology</i> , 2018, 144, 2195-2205.	2.5	35
67	Phase II results of GANNET53: A European multicenter phase I/randomized II trial of the Hsp90 inhibitor Ganetespib (G) combined with weekly Paclitaxel (P) in women with high-grade serous, high-grade endometrioid, or undifferentiated, platinum-resistant epithelial ovarian, fallopian tube or primary peritoneal cancer.. <i>Journal of Clinical Oncology</i> , 2018, 36, 5567-5567.	1.6	5
68	Prognostic Factors after Percutaneous Radiofrequency Ablation in the Treatment of Hepatocellular Carcinoma. Impact of Incomplete Ablation on Recurrence and Overall Survival Rates. <i>Journal of Gastrointestinal and Liver Diseases</i> , 2018, 27, 399-407.	0.9	29
69	Role of HYAL1 expression in primary breast cancer in the formation of brain metastases. <i>Breast Cancer Research and Treatment</i> , 2017, 162, 427-438.	2.5	10
70	History of hypertension, heart disease, and diabetes and ovarian cancer patient survival: evidence from the ovarian cancer association consortium. <i>Cancer Causes and Control</i> , 2017, 28, 469-486.	1.8	28
71	History of thyroid disease and survival of ovarian cancer patients: results from the Ovarian Cancer Association Consortium, a brief report. <i>British Journal of Cancer</i> , 2017, 117, 1063-1069.	6.4	16
72	No Evidence That Genetic Variation in the Myeloid-Derived Suppressor Cell Pathway Influences Ovarian Cancer Survival. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2017, 26, 420-424.	2.5	3

#	ARTICLE	IF	CITATIONS
73	LION: Lymphadenectomy in ovarian neoplasmsâ€”A prospective randomized AGO study group led gynecologic cancer intergroup trial.. Journal of Clinical Oncology, 2017, 35, 5500-5500.	1.6	81
74	TRUST: Trial of radical upfront surgical therapy in advanced ovarian cancer (ENGOT ov33 / AGOâ€”OVAR) Tj ETQq0 Q 0 rgBT / Overlock 10	1.6	75
75	Perioperative positioning management in gynecologic cancer surgery: A national NOGGO-AGO intergroup survey.. Journal of Clinical Oncology, 2017, 35, e17046-e17046.	1.6	0
76	Participation of elderly gynecological cancer patients in clinical trials.. Journal of Clinical Oncology, 2017, 35, e21520-e21520.	1.6	0
77	Correlation of isotope count with sentinel node positivity in vulvar cancer.. Journal of Clinical Oncology, 2017, 35, e17033-e17033.	1.6	0
78	Temsirolimus in women with platinum-refractory/resistant ovarian cancer or advanced/recurrent endometrial carcinoma. A phase II study of the AGO-study group (AGO-GYN8). Gynecologic Oncology, 2016, 140, 450-456.	1.4	58
79	Patterns of distant metastases in vulvar cancer. Gynecologic Oncology, 2016, 142, 427-434.	1.4	47
80	Role of tumour-free margin distance for loco-regional control in vulvar cancerâ€”a subset analysis of the Arbeitsgemeinschaft GynÃkologische Onkologie CaRE-1 multicenter study. European Journal of Cancer, 2016, 69, 180-188.	2.8	64
81	The Risk of Contralateral Non-sentinel Metastasis in Patients with Primary Vulvar Cancer and Unilaterally Positive Sentinel Node. Annals of Surgical Oncology, 2016, 23, 2508-2514.	1.5	37
82	Contrast enhanced ultrasonography in assessing the treatment response to transarterial chemoembolization in patients with hepatocellular carcinoma.. Medical Ultrasonography, 2016, 18, 96.	0.8	18
83	p16 overexpression and 9p21 deletion are linked to unfavorable tumor phenotype in breast cancer. Oncotarget, 2016, 7, 81322-81331.	1.8	31
84	The course of vulvar cancer: The utility of multistate models in the AGO-CaRE-1 study.. Journal of Clinical Oncology, 2016, 34, 5596-5596.	1.6	0
85	Old versus New â€” Tumor Ablation versus Tumor Nanoablation with Particular Emphasis on Liver Tumors. , 2015, , .		0